Establishing the Mutational Spectrum of Hungarian Patients with Familial Hypercholesterolemia

Genes (Basel). 2022 Jan 15;13(1):153. doi: 10.3390/genes13010153.

Abstract

Familial hypercholesterolemia (FH) is one of the most common autosomal, dominantly inherited diseases affecting cholesterol metabolism, which, in the absence of treatment, leads to the development of cardiovascular complications. The disease is still underdiagnosed, even though an early diagnosis would be of great importance for the patient to receive proper treatment and to prevent further complications. No studies are available describing the genetic background of Hungarian FH patients. In this work, we present the clinical and molecular data of 44 unrelated individuals with suspected FH. Sequencing of five FH-causing genes (LDLR, APOB, PCSK9, LDLRAP1 and STAP1) has been performed by next-generation sequencing (NGS). In cases where a copy number variation (CNV) has been detected by NGS, confirmation by multiplex ligation-dependent probe amplification (MLPA) has also been performed. We identified 47 causal or potentially causal (including variants of uncertain significance) LDLR and APOB variants in 44 index patients. The most common variant in the APOB gene was the c.10580G>A p.(Arg3527Gln) missense alteration, this being in accordance with literature data. Several missense variants in the LDLR gene were detected in more than one index patient. LDLR variants in the Hungarian population largely overlap with variants detected in neighboring countries.

Keywords: APOB; FH; Hungary; LDLR; NGS; familial hypercholesterolemia; next-generation sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Apolipoprotein B-100 / genetics
  • DNA Copy Number Variations*
  • Female
  • Genetic Markers*
  • Genetic Predisposition to Disease*
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Hungary / epidemiology
  • Hyperlipoproteinemia Type II / epidemiology
  • Hyperlipoproteinemia Type II / genetics
  • Hyperlipoproteinemia Type II / pathology*
  • Male
  • Middle Aged
  • Mutation*
  • Phenotype
  • Proprotein Convertase 9 / genetics
  • Receptors, LDL / genetics
  • Young Adult

Substances

  • Apolipoprotein B-100
  • Genetic Markers
  • Receptors, LDL
  • PCSK9 protein, human
  • Proprotein Convertase 9